Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The HA-1A saga: the scientific and ethical dilemma of innovative and costly therapies.

× No keyword cloud information.

12 in total

1. Antiendotoxin monoclonal antibodies for gram-negative sepsis: guidelines from the IDSA.

Authors: R P Wenzel; V T Andriole; J G Bartlett; M D Batt; W E Bullock; C G Cobbs; B Light; M A Martin; J Sanford; M A Sande
Journal: Clin Infect Dis Date: 1992-04 Impact factor: 9.079

Review 2. The regulation of investigational drugs.

Authors: D A Kessler
Journal: N Engl J Med Date: 1989-02-02 Impact factor: 91.245

3. Anti-endotoxin monoclonal antibodies.

Authors: H S Warren; R L Danner; R S Munford
Journal: N Engl J Med Date: 1992-04-23 Impact factor: 91.245

4. Anti-endotoxin monoclonal antibodies--a second look.

Authors: R P Wenzel
Journal: N Engl J Med Date: 1992-04-23 Impact factor: 91.245

5. Monoclonal antibodies to endotoxin. New allies against sepsis?

Authors: R C Bone
Journal: JAMA Date: 1991-08-28 Impact factor: 56.272

6. Critical appraisal of therapeutic interventions in the intensive care unit: human monoclonal antibody treatment in sepsis. Journal Club of the Hamilton Regional Critical Care Group.

Authors: D J Cook; R Jaeschke; G H Guyatt
Journal: J Intensive Care Med Date: 1992 Nov-Dec Impact factor: 3.510

7. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin.

Authors: J M Luce
Journal: Crit Care Med Date: 1993-08 Impact factor: 7.598

8. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.

Authors:
Journal: Arch Intern Med Date: 1994-11-14

9. HA-1A in septic patients with ARDS: results from the pivotal trial.

Authors: L M Bigatello; R E Greene; C L Sprung; E A Panacek; R C Straube; J L Zimmerman; R J Maunder; P N Lanken; E Pile-Spellmann; K S Stanek
Journal: Intensive Care Med Date: 1994-05 Impact factor: 17.440

10. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent.

Authors: K A Schulman; H A Glick; H Rubin; J M Eisenberg
Journal: JAMA Date: 1991-12-25 Impact factor: 56.272

2 in total

Review 1. The cytokine response to critical illness.

Authors: B A Foëx; M P Shelly
Journal: J Accid Emerg Med Date: 1996-05

Review 2. Human monoclonal antibodies from transgenic mice.

Authors: N Lonberg
Journal: Handb Exp Pharmacol Date: 2008

2 in total